Results 1 to 10 of about 5,217,497 (361)

Exosomes promote pre-metastatic niche formation in ovarian cancer. [PDF]

Molecular Cancer, 2019
Ovarian cancer is one of the most common gynecological malignancies. Upon initial diagnosis, the majority of patients present with widespread metastatic growth within the peritoneal cavity. This metastatic growth occurs in stages, with the formation of a
Dean, Dylan C, Duan, Zhenfeng, Feng, Wenlong, Hornicek, Francis J, Shi, Huirong   +4 more
core   +3 more sources

TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer [PDF]

BioImpacts, 2022
Introduction: Tumor endothelial marker 1 (TEM1) is expressed by tumor vascular endothelial cells in various cancers. Methods: Here, we developed poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) PEGylated with polyethylene glycol (PEG) and ...
Efthymia-Iliana Matthaiou, Yi Guo, Jaleh Barar, Raphael Sandaltzopoulos, Lana E. Kandalaft, Chunsheng Li, George Coukos, Yadollah Omidi   +7 more
doaj   +1 more source

Loss of LKB1-NUAK1 signalling enhances NF-κB activity in a spheroid model of high-grade serous ovarian cancer

Scientific Reports, 2022
High-grade serous ovarian cancer (HGSOC) is an aggressive malignancy often diagnosed at an advanced stage. Although most HGSOC patients respond initially to debulking surgery combined with cytotoxic chemotherapy, many ultimately relapse with platinum ...
Adrian Buensuceso, Jamie Lee Fritz, Olga Collins, Yudith Ramos Valdés, Matthew J. Borrelli, Gabriel E. DiMattia, Trevor G. Shepherd   +6 more
doaj   +1 more source

NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.

The Journal of the National Comprehensive Cancer Network, 2022
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years following diagnosis.
D. Armstrong, Ronald D. Alvarez, F. Backes, J. Bakkum-Gamez, L. Barroilhet, K. Behbakht, A. Berchuck, Lee-may Chen, Viola C Chitiyo, M. Cristea, M. DeRosa, E. Eisenhauer, D. Gershenson, H. Gray, Rachel Grisham, A. Hakam, Angela Jain, A. Karam, G. Konecny, Charles A Leath Iii, G. Leiserowitz, Joyce F. Liu, Lainie P Martin, D. Matei, M. McHale, K. McLean, D. Miller, Sanja Percac-Lima, S. Remmenga, J. Schorge, D. Stewart, P. Thaker, R. Vargas, A. W. Hendrickson, T. Werner, Emese Zsíros, M. Dwyer, Lisa E Hang   +37 more
semanticscholar   +1 more source

Gain-of-function p53R175H blocks apoptosis in a precursor model of ovarian high-grade serous carcinoma

Scientific Reports, 2023
Ovarian high-grade serous carcinoma (HGSC) is a highly lethal malignancy for which early detection is a challenge and treatment of late-stage disease is ineffective. HGSC initiation involves exfoliation of fallopian tube epithelial (FTE) cells which form
Jacob Haagsma, Bart Kolendowski, Adrian Buensuceso, Yudith Ramos Valdes, Gabriel E. DiMattia, Trevor G. Shepherd   +5 more
doaj   +1 more source

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

The Journal of the National Comprehensive Cancer Network, 2021
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and is the country's fifth most common cause of cancer mortality in women.
D. Armstrong, R. Alvarez, J. Bakkum-Gamez, L. Barroilhet, K. Behbakht, A. Berchuck, Lee-may Chen, M. Cristea, M. DeRosa, E. Eisenhauer, D. Gershenson, H. Gray, Rachel Grisham, A. Hakam, Angela Jain, A. Karam, G. Konecny, C. Leath, Joyce F. Liu, H. Mahdi, Lainie P Martin, D. Matei, M. McHale, K. McLean, D. Miller, D. O’Malley, Sanja Percac-Lima, E. Ratner, S. Remmenga, R. Vargas, T. Werner, Emese Zsíros, J. Burns, Anita M. Engh   +33 more
semanticscholar   +1 more source

Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer

Cell Death and Disease, 2022
PARP inhibitors (PARPi) have revolutionized the therapeutic landscape of epithelial ovarian cancer (EOC) treatment with outstanding benefits in regard to progression-free survival, especially in patients either carrying BRCA1/2 mutations or harboring ...
Ricardo Coelho, Alessandra Tozzi, Muriel Disler, Flavio Lombardo, André Fedier, Mónica Núñez López, Florian Freuler, Francis Jacob, Viola Heinzelmann-Schwarz   +8 more
doaj   +1 more source

Worldwide Burden, Risk Factors, and Temporal Trends of Ovarian Cancer: A Global Study

Cancers, 2022
Simple Summary Ovarian cancer was the third most common gynecological cancer globally in 2020. Ovarian carcinoma is the most common type of ovarian cancer, comprising over 90% of all ovarian cancer cases.
Junjie Huang, Wing Chung Chan, C. Ngai, Veeleah Lok, Lin Zhang, D. Lucero‐Prisno, Wanghong Xu, Zhi‐Jie Zheng, Edmar Elcarte, M. Withers, Martin C. S. Wong, On Behalf Of Ncd Global Health Research Group Of A   +11 more
semanticscholar   +1 more source

Activated CAMKKβ-AMPK signaling promotes autophagy in a spheroid model of ovarian tumour metastasis

Journal of Ovarian Research, 2020
Background A hallmark of epithelial ovarian cancer (EOC) metastasis is the process of spheroid formation, whereby tumour cells aggregate into 3D structures while in suspension in the peritoneal cavity.
Jeremi Laski, Bipradeb Singha, Xu Wang, Yudith Ramos Valdés, Olga Collins, Trevor G. Shepherd   +5 more
doaj   +1 more source

L1CAM is required for early dissemination of fallopian tube carcinoma precursors to the ovary

Communications Biology, 2022
L1CAM is implicated as an important factor that enables early fallopian tube cancer precursors to seed the ovary by promoting cell survival through extracellular matrix signaling, thereby facilitating ovarian cancer growth.
Kai Doberstein, Rebecca Spivak, Hunter D. Reavis, Jagmohan Hooda, Yi Feng, Paul T. Kroeger, Sarah Stuckelberger, Gordon B. Mills, Kyle M. Devins, Lauren E. Schwartz, Marcin P. Iwanicki, Mina Fogel, Peter Altevogt, Ronny Drapkin   +13 more
doaj   +1 more source